IMBRUVICA® is indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion

INN:

Subtype:

Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

License:

FDA

Class:

BTK inhibitor

Newly Diagnosed

PI: https://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf 

1. Approved Labelling 

Imbruvica is indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with 17p deletion

2. Treatment Regimen 

The recommended dose of Imbruvica for CLL/SLL is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity. The recommended dose of IMBRUVICA for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

3. AE/Warnings

Please see section 5 of the PI. 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.